Cochrane Review: Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes

Zusammenfassung

Natrium‐Glucose‐Cotransporter‐2 ­(SGLT2)‐Inhibitoren für Menschen mit chronischer Nierenerkrankung und Diabetes - Natale, P - 2024 \| Cochrane Library [Skip to Content](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015588.pub2/full/de#main-content) [Close cookies message](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015588.pub2/full/de#) Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, incl

Kerninformationen

8.pub2/full/de#) [Cochrane Database of Systematic reviews](https://www.cochranelibrary.com/en/about/about-cochrane-reviews) Review - Intervention Collapse all Expand all ## Abstract available in ### Background Diabetes is associated with high risks of premature chronic kidney disease (CKD), c...

ng rapidly, and evidence synthesis is essential to summarising cumulative evidence. ### Objectives This review aimed to assess the benefits and harms of SGLT2 inhibitors for people with CKD and diabetes. ### Search methods We searched the Cochrane Kidney and Transplant Register of Studies up to ...

diabetes. CKD includes all stages (from 1 to 5), including dialysis patients. ### Data collection and analysis Two authors independently extracted data and assessed the study risk of bias. Treatment estimates were summarised using random effects meta‐analysis and expressed as a risk ratio (RR) or...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen